Supriya Lifescience has successfully completed an inspection by the U.S. Food and Drug Administration (US FDA) at its manufacturing facility in Lote, Maharashtra. The inspection, conducted from 2 February 2026 to 6 February 2026, resulted in a Form 483 with a single minor observation. The company has addressed this observation and has received an Establishment Inspection Report (EIR) indicating ‘Voluntary Action Indicated (VAI)’, marking the inspection’s successful completion.
The company emphasises its commitment to maintaining full compliance with current Good Manufacturing Practice (cGMP) requirements across all its manufacturing facilities. This update has been disclosed under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Disclaimer: This article is based on a regulatory filing submitted to the National Stock Exchange of India (NSE).
This article is written by Kinjal and reviewed by Aman Shukla before publication.